Education
About Us
Working with TipRanks
Follow Us
Alibaba Health Information Technology Ltd. (CH:TWY)
:TWY
See the Price Targets and Ratings of:
TWY Financial Forecast
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Macquarie
CHF0.36
Sell
―
Reiterated
12/30/24
Macquarie Reiterates Underperform Rating on Alibaba Health (241:HK)Macquarie analyst Ellie Jiang reiterated an Underperform rating and HK$3.40 price target on Alibaba Health (241:HK).
Goldman Sachs
CHF0.46→CHF0.42
Hold
―
Downgraded
11/28/24
Goldman Sachs Downgrades Alibaba Health (241:HK) to NeutralGoldman Sachs analyst Lincoln Kong downgraded Alibaba Health (241:HK) from Buy to Neutral with a price target of HK$4.00 (from HK$4.40).
CLSA
CHF0.47→CHF0.5
Buy
―
Reiterated
11/15/24
Alibaba Health (241:HK) PT Raised to HK$4.80 at CLSACLSA analyst Wenting Yu raised the price target on Alibaba Health (241:HK) to HK$4.80 (from HK$4.50) while maintaining a Outperform (2) rating.
Morgan Stanley
CHF0.52
Buy
―
Reiterated
11/15/24
Positive Revenue and Profit Growth Drive 24% Upside Potential for Alibaba Health Information Technology
Unknown Analyst
Not Ranked
Jefferies
CHF0.63
Buy
―
Reiterated
10/25/24
Bank of America Securities
CHF0.47→CHF0.48
Buy
―
Reiterated
10/16/24
Alibaba Health (241:HK) PT Raised to HK$4.60 at BofA SecuritiesBofA Securities analyst Miranda Zhuang raised the price target on Alibaba Health (241:HK) to HK$4.60 (from HK$4.50) while maintaining a Buy rating.
HSBC
CHF0.44
Buy
―
Reiterated
09/25/24
HSBC Reiterates Buy Rating on Alibaba Health (241:HK)HSBC analyst Charlene Liu reiterated a Buy rating and HK$4.20 price target on Alibaba Health (241:HK).
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Macquarie
CHF0.36
Sell
―
Reiterated
12/30/24
Macquarie Reiterates Underperform Rating on Alibaba Health (241:HK)Macquarie analyst Ellie Jiang reiterated an Underperform rating and HK$3.40 price target on Alibaba Health (241:HK).
Goldman Sachs
CHF0.46→CHF0.42
Hold
―
Downgraded
11/28/24
Goldman Sachs Downgrades Alibaba Health (241:HK) to NeutralGoldman Sachs analyst Lincoln Kong downgraded Alibaba Health (241:HK) from Buy to Neutral with a price target of HK$4.00 (from HK$4.40).
CLSA
CHF0.47→CHF0.5
Buy
―
Reiterated
11/15/24
Alibaba Health (241:HK) PT Raised to HK$4.80 at CLSACLSA analyst Wenting Yu raised the price target on Alibaba Health (241:HK) to HK$4.80 (from HK$4.50) while maintaining a Outperform (2) rating.
Morgan Stanley
CHF0.52
Buy
―
Reiterated
11/15/24
Positive Revenue and Profit Growth Drive 24% Upside Potential for Alibaba Health Information Technology
Unknown Analyst
Not Ranked
Jefferies
CHF0.63
Buy
―
Reiterated
10/25/24
Bank of America Securities
CHF0.47→CHF0.48
Buy
―
Reiterated
10/16/24
Alibaba Health (241:HK) PT Raised to HK$4.60 at BofA SecuritiesBofA Securities analyst Miranda Zhuang raised the price target on Alibaba Health (241:HK) to HK$4.60 (from HK$4.50) while maintaining a Buy rating.
HSBC
CHF0.44
Buy
―
Reiterated
09/25/24
HSBC Reiterates Buy Rating on Alibaba Health (241:HK)HSBC analyst Charlene Liu reiterated a Buy rating and HK$4.20 price target on Alibaba Health (241:HK).
Best Analysts Covering Alibaba Health Information Technology
Which Analyst Should I Follow If I Want to Buy CH:TWY and Sell After:
1 Month
xxx
Success Rate
2/3 ratings generated profit
Average Return
+6.00%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +6.00% per trade.
3 Months
xxx
Success Rate
1/2 ratings generated profit
Average Return
+21.50%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +21.50% per trade.
1 Year
Success Rate
2/2 ratings generated profit
Average Return
+13.45%
reiterated a buy rating 5 months ago
Copying Wenting Yu's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +13.45% per trade.
2 Years
xxx
Success Rate
2/2 ratings generated profit
Average Return
+13.45%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +13.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
TWY Analyst Recommendation Trends
Rating
Jun 24
Sep 24
Oct 24
Nov 24
Dec 24
Strong Buy
4
5
5
6
4
Buy
0
0
0
0
0
Hold
2
2
1
1
1
Sell
0
0
1
2
3
Strong Sell
0
0
0
0
0
total
6
7
7
9
8
Each month's total comprises the sum of three months' worth of ratings.
TWY Stock Forecast FAQ
What is CH:TWY’s average 12-month price target, according to analysts?
Based on analyst ratings, Alibaba Health Information Technology Ltd.’s 12-month average price target is 0.39.
What is CH:TWY’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for CH:TWY, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Alibaba Health Information Technology Ltd. a Buy, Sell or Hold?
Alibaba Health Information Technology Ltd. has a consensus rating of Moderate Sell, which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
What is Alibaba Health Information Technology Ltd.’s share price target?
The average share price target for Alibaba Health Information Technology Ltd. is 0.39. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF0.39 ,and the lowest forecast is CHF0.39. The average share price target represents N/A Increase from the current price of N/A.
The highest analyst share price target is CHF0.39 ,and the lowest forecast is CHF0.39. The average share price target represents N/A Increase from the current price of N/A.
What do analysts say about Alibaba Health Information Technology Ltd.?
Alibaba Health Information Technology Ltd.’s analyst rating consensus is a Moderate Sell. This is based on the ratings of 0 Wall Streets Analysts.
How can I buy shares of Alibaba Health Information Technology Ltd.?
To buy shares of CH:TWY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.